Lupeng Pharmaceutical Co., Ltd. has recently submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with China Securities acting as the sole sponsor.

This marks the company's second attempt to list in Hong Kong, following an initial application in October 2025 which lapsed after six months without a hearing.

Since its establishment, the company has completed six rounds of financing, raising a cumulative total of approximately $213.2 million.

Following its Series B financing in September 2025, the company's post-money valuation was approximately $311.25 million.

Major healthcare investment institutions such as Kaitai Capital, Lilly Asia Ventures (LAV), OrbiMed, and Temasek are among its shareholders.

Financially, Lupeng Pharmaceutical exhibits the typical profile of a research-focused biotech firm, reporting a cumulative net loss of approximately RMB 210 million for 2024 and 2025, primarily due to sustained R&D expenditures.

A key point of market interest is the company's core product, LP-168 (brand name: Lu Ke Da), the world's first fourth-generation BTK inhibitor, which received marketing approval in June 2026.

With this flagship product, the question is whether Lupeng Pharmaceutical can capture the favor of Hong Kong investors in this listing attempt.

Core Product Has One Approved Indication, Two Others in Development

Founded in 2015, Lupeng Pharmaceutical is a biopharmaceutical company with its self-developed BeyondX oral drug chemistry platform, focusing on the design, discovery, clinical development, and commercialization of high-bioavailability oral drugs for cancer and autoimmune diseases globally.

The company has established a pipeline comprising six major candidate products, with three core assets at the new drug application and clinical stages: the core product LP-168, along with LP-108 and LP-118.

The core product LP-168 is a BTK inhibitor with a "covalent and non-covalent" binding mode.

This dual mechanism enables LP-168 to simultaneously clear tumor cells carrying both wild-type and drug-resistant mutant BTK, showing significant potential in both oncology and autoimmune diseases.

LP-168's potential indications include various tumors and autoimmune diseases, such as relapsed/refractory (R/R) mantle cell lymphoma (MCL), relapsed/refractory non-GCB diffuse large B-cell lymphoma (DLBCL), and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

For the MCL indication, study data showed that LP-168 achieved a higher response rate (63.9%) and a longer duration of disease control (progression-free survival: 7.4 months) in MCL patients.

In June 2026, LP-168 (Lubotinib tablets, brand name: Lu Ke Da) was approved for marketing in China for the treatment of adult MCL patients who have received at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.

For the DLBCL indication in adults who have received at least two prior lines of therapy, the drug was included in the National Medical Products Administration's breakthrough therapy designation list in May 2024, with the corresponding pivotal registrational Phase II clinical study (ROCK-2) initiated by the end of 2025.

For the CLL indication in patients previously treated with a BTK inhibitor, results from a Phase I study conducted in the US showed an objective response rate (ORR) of 78.3% and an estimated median progression-free survival (mPFS) of 28.1 months for Lubotinib treatment.

Beyond these three primary indications, the company also plans to expand into the autoimmune field in the future, having already initiated a clinical study of LP-168 for chronic spontaneous urticaria (CSU) in China.

Development for non-oncology indications is primarily handled by its partner, Hansoh Pharmaceutical, to which Lupeng sold the rights for the R&D, registration, production, and commercialization of all non-oncology indications of Lubotinib in China (including Hong Kong, Macau, and Taiwan) in August 2024, for a total transaction value exceeding RMB 700 million.

Additionally, the company has two other investigational drugs in Phase II clinical trials: the selective Bcl-2 inhibitor LP-108 (Letuokela, Lacutoclax) and the oral Bcl-2/Bcl-xL dual inhibitor LP-118, both with the potential to become best-in-class products.

BTK Inhibitor Market is Crowded: What is Lupeng's Potential?

BTK inhibitors are a class of targeted anticancer drugs that act on Bruton's tyrosine kinase (BTK), primarily exerting their therapeutic effects by regulating the B-cell receptor (BCR) signaling pathway.

This pathway is crucial for the survival, proliferation, differentiation, and migration of B cells, and its abnormal activation is closely related to the development and progression of various B-cell malignancies.

In terms of technological generations, first-generation BTK inhibitors, represented by ibrutinib, have poor selectivity and also inhibit targets like EGFR and TEC, leading to off-target effects and more adverse reactions.

Second-generation products, such as zanubrutinib, orelabrutinib, and acalabrutinib, maintain high selectivity while reducing off-target toxicity, improving both safety and efficacy.

Unlike the first two generations, third-generation BTK inhibitors do not rely on covalent binding to the C481 site of the BTK protein, thus effectively overcoming acquired resistance caused by the C481S mutation to first- and second-generation covalent BTK inhibitors.

Represented by pirtobrutinib, third-generation inhibitors bind to BTK non-covalently via hydrogen bonds and are indicated for patients who have received at least two prior lines of systemic therapy, including a BTK inhibitor.

According to the prospectus, Lupeng's LP-168 can bind to wild-type BTK covalently (matching first-generation efficacy) and to C481S mutant BTK non-covalently (addressing resistance), hence its designation as a fourth-generation BTK inhibitor.

The competitive landscape for BTK inhibitors is becoming increasingly crowded.

To date, five first- and second-generation BTK inhibitors are approved globally, and Lilly's third-generation pirtobrutinib was approved in China in October 2024.

Several non-covalent BTK inhibitors from companies like Roche and Merck are also in clinical stages, indicating intense market competition.

Analyzing the specific market potential shows that despite facing multiple competitors and limited efficacy, first-generation ibrutinib still generated $3 billion in sales in the first half of 2025.

BeiGene's zanubrutinib, the first and only BTK inhibitor approved for follicular lymphoma globally, achieved sales of $1.742 billion in the first half of 2025, a year-on-year increase of 54.7%, thanks to this unique position.

Lilly's pirtobrutinib reached global sales of $337 million in 2024, with revenue in Q1 2025 further climbing to $92 million, a surge of 84% year-on-year.

For the MCL indication, while Lupeng's Lubotinib has been approved, it will face competition from five similar products, including Lilly's pirtobrutinib.

Its ability to capture market share from incumbents will largely depend on future head-to-head clinical trial results.

In January 2026, a global Phase III head-to-head trial of Lubotinib versus the third-generation non-covalent BTK inhibitor pirtobrutinib for treating R/R CLL/SLL was officially initiated.

This study is expected to complete patient enrollment by the end of 2027, with an interim analysis in 2029.

In contrast, the DLBCL indication holds stronger scarcity and potentially higher future growth elasticity.

Information indicates that Lubotinib is the first and only BTK inhibitor in China, and globally, to have received such designation for the R/R non-GCB DLBCL indication in adults who have received at least two prior lines of therapy.

Looking at Lupeng's subsequent pipeline, the company has also developed two drugs targeting the BCL-2 pathway.

The BCL-2 protein, as an anti-apoptotic regulator, is highly expressed in various hematological malignancies and solid tumors, helping cancer cells evade programmed death, making BCL-2 inhibitors an important direction in cancer therapy.

Currently, three BCL-2 inhibitors are approved in China, such as AbbVie's venetoclax and BeiGene's sonrotoclax, with products from companies like Chia Tai Tianqing and InnoCare in clinical development.

Lupeng's LP-108 and LP-118 are both in Phase II clinical trials and will face a relatively competitive environment upon potential future approval.

Conclusion

Lupeng Pharmaceutical's push for a Hong Kong listing coincides with the critical juncture of its core product LP-168's recent market approval.

As the world's first fourth-generation BTK inhibitor, it possesses significant commercial potential but must await results from subsequent head-to-head trials against pirtobrutinib, making it difficult to establish a differentiated competitive barrier in the short term.

While the DLBCL indication is highly unique, it is still in Phase II clinical trials, with commercialization still some way off.

Furthermore, Lubotinib's current approval is only for later-line therapy, which limits its immediate addressable market.

Future demonstration of superiority over existing competitors in front-line treatment could potentially unlock a much larger market.

Overall, Lupeng Pharmaceutical represents a high-volatility investment proposition with both fundamental strengths and competitive risks, characteristic of the high-risk, high-reward nature of innovative drug development, making its Hong Kong IPO worthy of long-term investor attention.